ClinicalTrials.gg
RecruitingNCT06042387Updated Oct 9, 2026

Genome Analysis Across Populations in Inflammatory Bowel Disease

An observational study in Ulcerative Colitis, Healthy and Crohn Disease, sponsored by Mount Sinai Hospital, Canada. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Mount Sinai Hospital, Canada · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Colitis, Ulcerative with a site in Canada — 47 open to participants now, 84 under way, 24 of them phase 3. Colitis, Ulcerative · Canada.

Planned enrollment
21st of 38
150 · median 197
Started
2022
with 12 others
Observational
38 of 265
7 open now
Primary completion
2027-05
later than 37 of 83 live
Registered
211th of 265
by date
Lead sponsor
9 of 265
Mount Sinai Hospital, Canada

Among the 265 studies in Colitis, Ulcerative with a site in Canada, this one is the 21st largest by planned enrollment of the 38 observational ones that give a count, is one of 13 that started in 2022, is one of 38 observational ones, reaches primary completion later than 37 of the 83 other live ones, and was the 211th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

47 of the 265 studies in Colitis, Ulcerative with a site in Canada are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Colitis, Ulcerative with a site in Canada, or all of them as a file.
02

Study summary

Objective:

To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.

Read the detailed description

Background:

Inflammatory bowel disease (IBD) is a chronic, and often disabling, disorder of the intestines characterized by dysregulation of mucosal immune response. Recent data suggests that the incidence and prevalence rates among all populations may be increasing due to constantly changing environmental exposures. The goal of the study is to identify susceptible genes that contribute to the pathogenesis of IBD in affected individuals.

03

Conditions studied

  • Ulcerative Colitis
  • Healthy
  • Crohn Disease
  • Inflammatory Bowel Diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

IBD or Healthy controls (non-IBD)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
  • Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
  • Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
  • Any age

Exclusion criteria

Exclusion Criteria:

- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • IBD Subjects

    Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) Any age Willing to provide blood or saliva sample

    Genetic: Blood or saliva sample collection

  • Controls

    No personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss Any age Willing to provide blood or saliva sample

    Genetic: Blood or saliva sample collection

Interventions

  • GeneticBlood or saliva sample collection

    Blood or saliva sample \& clinical data collection

06

What researchers measure

Primary outcomes

  1. Genomics studies across populations

    Whole Exome Sequencing (+/- other sequencing) is planned

    Time frame: 2022-2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 60 months is above that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Sep 18, 2023
StartActual
May 1, 2022
Primary completionEst.
May 2027
CompletionEst.
Sep 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, oversight details, criteria formatting and site details
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 5 other changes: index terms, verification date, oversight details, criteria formatting and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06042387
Responsible party
Mark Silverberg (Dr., Mount Sinai Hospital, Canada) — Principal investigator
First posted
Sep 18, 2023
Start date
May 1, 2022
Primary completion
May 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Joanne Stempak, MSc
Contact
joanne.stempak@sinaihealth.ca
4165864800 ext. 8399
Jenny Lee, MKin
Contact
jenny.lee2@sinaihealth.ca
416-586-4800 ext. 2318
Mark Silverberg, MD PhD
principal investigator · Sinai Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion